Boehringer Ingelheim v. Hetero USA: Consent Judgment on Linagliptin Patents
Boehringer Ingelheim filed suit against Hetero USA and Hetero Labs in Delaware District Court, asserting two patents covering linagliptin (Trajenta), a diabetes treatment. The case ended by consent judgment after 272 days, with Hetero acknowledging the validity and enforceability of both asserted patents.
ANDA challenge to Trajenta patents resolved by consent judgment
Boehringer Ingelheim Corporation, Boehringer Ingelheim Pharma GmbH & Co. KG, and Boehringer Ingelheim International GmbH (collectively, Boehringer Ingelheim) filed suit on 13 January 2023 in the Delaware District Court against Hetero USA, Inc. and Hetero Labs Limited. The action concerned Hetero's ANDA No. 217749, seeking approval for 5 mg linagliptin tablets as a generic version of Trajenta, a diabetes treatment indicated for patients inappropriate for metformin therapy. Two patents were asserted: US10034877B2 and US9486526B2.
The recorded basis of termination is Consent Judgment. The docket order establishing the consent judgment records that Hetero agrees both the '877 Patent (US10034877B2) and the '526 Patent (US9486526B2) are valid and enforceable, and defines the scope of 'Hetero ANDA Products' by reference to ANDA No. 217749 as it exists on the effective date and as amended or supplemented in the ordinary course of business. The consent judgment was entered as binding by the court, ending the litigation. The specific commercial terms of any related agreement between the parties are not disclosed in the available public record.
At 272 days, the case resolved well within the 30-month stay window that typically governs Hatch-Waxman ANDA litigation, which is consistent with an agreed resolution before substantive trial proceedings. Hetero's acknowledgment of validity and enforceability of both patents — rather than a simple procedural dismissal — suggests the consent judgment carries meaningful legal weight for future enforcement purposes. What drove the specific timing and terms of the agreement beyond what appears in the public record is not disclosed.
See Complete Case & Patent Analysis →Filing to Consent Judgment in 272 days
272 days from filing to consent judgment — a relatively swift resolution for ANDA patent litigation in Delaware
US10034877B2 & US9486526B2 — linagliptin tablets for diabetes treatment
Any generic pharmaceutical manufacturer considering an ANDA filing for a linagliptin-containing product — including 5 mg tablets or any formulation overlapping with Trajenta — should conduct a thorough freedom-to-operate analysis against both US10034877B2 and US9486526B2. The consent judgment in this case records Hetero's acknowledgment of validity and enforceability, which signals that Boehringer Ingelheim is willing to pursue and resolve ANDA-triggered litigation on these patents. Regulatory and R&D teams should also consider any related patents in the broader Boehringer Ingelheim linagliptin portfolio.
Official order — verbatim text
The consent judgment order records Hetero's explicit agreement that both the '526 Patent (US9486526B2) and the '877 Patent (US10034877B2) are valid and enforceable for purposes of this action, and defines the scope of 'Hetero ANDA Products' by reference to ANDA No. 217749. This on-record acknowledgment goes beyond a procedural resolution and may carry weight in future enforcement proceedings by Boehringer Ingelheim against other generic filers in the linagliptin space.
Consent judgment: what the agreed resolution means for both parties
A court-entered consent judgment — not merely a dismissal
A consent judgment is a binding judicial order entered on terms agreed by the parties. Unlike a voluntary dismissal, it carries the full weight of a court judgment and can be enforced directly. Here, the Delaware District Court entered judgment incorporating Hetero's acknowledgment that both the '877 and '526 patents are valid and enforceable. The specific terms of any related commercial agreement are not disclosed in the public record.
Binding court-entered judgmentBoehringer secures on-record validity acknowledgment from Hetero
The consent judgment records Hetero's explicit agreement that US10034877B2 and US9486526B2 are valid and enforceable. This on-record acknowledgment strengthens Boehringer Ingelheim's enforcement posture for these patents against future ANDA filers and generic challengers. The consent judgment also defines the Hetero ANDA Products by reference to ANDA No. 217749, providing a defined scope for any future enforcement action.
Validity acknowledged on recordHetero's market entry position defined by the agreed terms
By entering the consent judgment, Hetero USA and Hetero Labs agreed to the validity and enforceability of both asserted patents for purposes of this action. The consent judgment defines 'Hetero ANDA Products' in scope, including 5 mg linagliptin tablets under ANDA No. 217749. The specific commercial terms — including any agreed market entry date or licensing arrangement — are not disclosed in the available public record.
Market entry terms undisclosedConsent judgments with validity acknowledgments raise the bar for future challengers
When a generic filer acknowledges patent validity by consent judgment rather than contesting it, the public record becomes more favorable to the patent holder in subsequent Hatch-Waxman litigation. Competitors seeking to launch generic linagliptin products should assess both patents carefully. The breadth of the ANDA product definition — covering amendments in the ordinary course of business — may also be relevant to future formulation changes.
Strengthened enforcement postureFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Boehringer-Ingelheim | Individual | /Search in Eureka ↗ |
| Co-Plaintiff | Boehringer Ingelheim Corporation | Company | Search in Eureka ↗ |
| Co-Plaintiff | Boehringer Ingelheim Pharma Gmbh & Co., KG | Company | Search in Eureka ↗ |
| Co-Plaintiff | Boehringer Ingelheim International, GMBH | Company | Search in Eureka ↗ |
| Defendant | Hetero USA, Inc. | Company | /Search in Eureka ↗ |
| Co-Defendant | Hetero Labs Limited | Individual | Search in Eureka ↗ |
| Co-Defendant | Hetero Labs Limited | Individual | Search in Eureka ↗ |
| Plaintiff counsel | Brian P. Egan | Attorney | Counsel for Boehringer-IngelheimSearch in Eureka ↗ |
| Plaintiff counsel | Jack B. Blumenfeld | Attorney | Counsel for Boehringer-IngelheimSearch in Eureka ↗ |
| Plaintiff counsel | Megan Elizabeth Dellinger | Attorney | Counsel for Boehringer-IngelheimSearch in Eureka ↗ |
| Plaintiff law firm | Morris, Nichols, Arsht & Tunnell LLP | Law Firm | Representing Boehringer-IngelheimSearch in Eureka ↗ |
| Defendant counsel | Cortlan S. Hitch | Attorney | Counsel for Hetero USA, Inc.Search in Eureka ↗ |
| Defendant counsel | Kenneth Laurence Dorsney | Attorney | Counsel for Hetero USA, Inc.Search in Eureka ↗ |
| Defendant law firm | Morris James LLP | Law Firm | Representing Hetero USA, Inc.Search in Eureka ↗ |
| Presiding judge | Judge Colm F. Connolly | Judge | Delaware District CourtSearch in Eureka ↗ |
R&D signals in the linagliptin and DPP-4 inhibitor patent space
Forward-looking patent and R&D intelligence signals drawn from Boehringer Ingelheim's linagliptin IP position and the broader DPP-4 inhibitor landscape.
Boehringer Ingelheim's linagliptin patent filing activity
Boehringer Ingelheim's assertion of both US10034877B2 and US9486526B2 in a single ANDA action suggests a layered portfolio strategy around linagliptin. Monitoring the full family of patents and pending applications linked to these two grants can reveal the remaining exclusivity runway and whether new formulation or method claims are being pursued.
Linagliptin portfolio depthDPP-4 inhibitor patent filing trends beyond Trajenta
The DPP-4 inhibitor class — including sitagliptin, saxagliptin, and alogliptin alongside linagliptin — is a high-activity patent filing space. Tracking new formulation, combination, and indication patents in this class can signal where branded manufacturers are building next-generation exclusivity walls and where generic manufacturers face the greatest entry barriers.
DPP-4 class filing activityHetero Labs' patent and ANDA filing strategy in diabetes drugs
Hetero Labs is an active ANDA filer across multiple therapeutic areas. Mapping Hetero's own patent filings and ANDA paragraph IV certification history in the diabetes drug space can reveal where the company is building generic pipeline assets and which branded products it may target next.
Hetero ANDA pipeline signalsAdjacent formulation and combination opportunities near linagliptin
Linagliptin combination therapies — including fixed-dose combinations with metformin, empagliflozin, and other agents — represent an adjacent patent space where filing activity continues. R&D teams seeking differentiated positions in the type 2 diabetes space should map claim density around combination formulations to identify white-space opportunities not covered by existing Boehringer Ingelheim IP.
Combination therapy white spaceSimilar ANDA patent infringement cases involving linagliptin or DPP-4 inhibitors in Delaware
Explore comparable Hatch-Waxman ANDA patent infringement cases involving diabetes drug formulations litigated in the Delaware District Court.
What this case signals for the linagliptin and ANDA patent landscape
A consent judgment with explicit validity acknowledgments is a meaningful result in ANDA litigation — here is what it signals.
On-record validity admissions create durable enforcement leverage
Boehringer Ingelheim obtained Hetero's acknowledgment that both the '877 and '526 patents are valid and enforceable. This is stronger than a simple dismissal. Patent holders defending against subsequent ANDA filings can reference prior consent judgments as part of their enforcement narrative.
Resolution within 272 days suggests pre-trial leverage was sufficient
ANDA litigation in Delaware routinely runs past the 30-month stay. Settling well within that window — without a claim construction or validity ruling — suggests the parties reached commercial alignment early. For generics monitoring Trajenta, the clock may matter as much as the merits.
Boehringer-Ingelheim v Hetero — key questions answered
Two patents were asserted: US10034877B2 (application no. US15/287228) and US9486526B2 (application no. US14/294630), both covering linagliptin tablet formulations and methods. The products at issue were 5 mg linagliptin tablets filed under Hetero ANDA No. 217749 as a generic version of Trajenta.
The case ended by consent judgment entered by the Delaware District Court. The consent judgment records that Hetero agreed both the '877 Patent (US10034877B2) and the '526 Patent (US9486526B2) are valid and enforceable. The specific commercial terms of any related agreement between the parties are not disclosed in the available public record.
Yes, for purposes of this action. The consent judgment records Hetero's agreement that both US10034877B2 and US9486526B2 are valid and enforceable. This is an on-record acknowledgment, though it is expressly limited to the scope of this action.
The case was filed on 13 January 2023 and closed on 12 October 2023 — a duration of 272 days. This is notably swift for ANDA patent litigation in Delaware, which frequently runs past the 30-month Hatch-Waxman stay period before resolution.
A consent judgment is a binding court-entered order, not merely a procedural dismissal. Where — as here — the consent judgment includes the generic filer's acknowledgment that the asserted patents are valid and enforceable, it strengthens the patent holder's enforcement posture against subsequent ANDA filers. Future generic challengers to Trajenta patents should account for this public record when assessing litigation risk.
This page is compiled from public court dockets and third-party patent and litigation data via PatSnap Eureka, and is provided for general informational purposes only. The information shown — including party names, patent and application numbers, dates, case status, outcomes, and any analysis — may be incomplete, may not reflect the most recent filings or legal status, and may contain errors or omissions. Verify all details against official court records (for example, PACER) and the relevant patent office before relying on them.
Nothing on this page constitutes legal advice or a legal opinion on the validity, infringement, enforceability, or scope of any patent or case, and no attorney‑client relationship is created by its use. Any description of an outcome (such as a dismissal, settlement, or consent judgment) is a general summary, not a legal determination. All patents, trademarks, and company or law‑firm names are the property of their respective owners. PatSnap makes no warranty as to the accuracy or completeness of this content and disclaims, to the fullest extent permitted by law, all liability for reliance on it. For advice on a specific matter, consult qualified legal counsel.
PatSnap Eureka searches patents and litigation data to answer instantly.